ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Scientifically-designed fasting diet lowers risks for major diseases

More evidence for calorie restriction’s longevity effect

Supplementation with vitamin D associated with improved testosterone, erectile function among middle...

Vitamin D deficiency increases risk of chronic headache

Get the Most From Your Green Tea

VIDEO: The Best Brain Foods That Help Increase Your Memory!

Acupuncture boosts effectiveness of standard medical care for chronic pain, depression

Iron (And More) For Lasting, Natural Energy

Metabolic syndrome increases the need for vitamin E

Supplement combo improves bone density, mood, in postmenopausal women

 
Print Page
Email Article

Statin Drug May Slow Multiple Sclerosis Lesion Progression in Early Stage Patients

  [ 6 votes ]   [ Discuss This Article ]
www.ProHealth.com • April 30, 2010


“We need a larger study to confirm the effects of the drug and its magnitude…[and] “to learn whether a relatively inexpensive oral therapy can slow the course of disease.”

A study examining the impact of statins on the progression of multiple sclerosis (MS) has found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

Participants received an 80 milligram daily dose of atorvastatin, (brand name Lipitor), according to researchers at University of California, San Francisco, who led the study involving 13 leading medical centers in the US & Canada.

Although the study was small with only 81 participants and its primary endpoint, designed to evaluate MS progression in patients following their first attack, was not met, the researchers found over the 12-month course that 55.3% of participants did not develop new brain lesions when administered statins, compared with 27.6% of the placebo group.

Study findings were presented April 14, 2010 by UCSF researchers during the annual American Academy of Neurology scientific meeting in Toronto.

The trial was a phase II, multi-center, randomized, placebo-controlled follow up to a landmark study published by principal investigator Dr. Scott S. Zamvil, MD,  associate professor of neurology at UCSF (Youssef, et al., Nature 2002), after his laboratory first observed that statins cause T cell immune modulation that could be beneficial in multiple sclerosis and other autoimmune diseases.

Co-led by Zamvil and Dr. Emmanuelle Waubant, MD, PhD, associate professor of neurology at the UCSF MS Center, the study tested whether the drug could be used to prevent conversion to definite multiple sclerosis in individuals who have had a first attack.

"Our data is preliminary, and we need a larger study to confirm the effects of the drug and its magnitude,” said Waubant. “It is important that we understand how statins impact the progression of multiple sclerosis in order to better inform physicians and patients of their effect, since these drugs are so broadly used throughout the United States and the world, and to learn whether a relatively inexpensive oral therapy can slow the course of disease."

MS is considered an autoimmune disease where immune cells attack the central nervous system. Nerves are made up of axons (nerve fibers) surrounded by a myelin sheath. MS occurs when the immune system attacks myelin, leaving scars or lesions in the demyelinated areas of the brain and spinal cord. Damage to myelin disrupts the ability of nerves to transmit information to nerve cells, resulting in neurological disability.

The team employed MRI to look at the activity of the medication on the disease course. More than 150 patients were originally intended, but enrollment was stopped due to slow recruitment after 81 patients were randomized. Each subject was asked to come in every three months (five scans over 12 months) for serial brain MRI evaluation. The subject pool was 76.5% female, 92.6% white, and ranged in age from 24 to 48 years.

Central MRI reading and coordinating was provided by Dr. Daniel Pelletier, associate professor of neurology and a member of the Multiple Sclerosis Research Group at UCSF.

"The exciting finding in this study is that reducing new brain MRI lesions should be meaningful for patients since new lesions are reliable correlates of future clinical attacks in MS," said Pelletier.

In addition to UCSF, the multi-center trial involved Oregon Health & Science University, The Cleveland Clinic, Virginia Mason MS Center, Washington University School of Medicine John L. Trotter MS Center, Montreal Neurological Institute, Barrow Neurological Institute, University of Texas Southwestern Medical Center, University of Rochester, The Multiple Sclerosis Comprehensive Care Center at USC Keck School of Medicine, Yale MS Research Center, Jacobs Neurological Institute, Johns Hopkins University and Mount Sinai School of Medicine.

The research was performed as a project of the Immune Tolerance Network, a clinical research consortium headquartered at UCSF and sponsored by the National Institute of Allergy & Infectious Diseases.

Source: University of California-San Francisco Medical Center news release, Apr 14, 2010




Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra EPA  - Fish Oil FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Joint Aches May Have Met Their Match in Curcumin Joint Aches May Have Met Their Match in Curcumin
Bone Broth Benefits for Digestion, Arthritis and Cellulite Bone Broth Benefits for Digestion, Arthritis and Cellulite
Fatigue & Fibro Fog: Could You Have a B-12 Deficiency? Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?
Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed
Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map